Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring

被引：0
|
作者：
Gonczi, L. [1 ]
Ilias, A. [1 ]
Szanto, K. [2 ]
Kurti, Z. [1 ]
Golovics, P. A. [3 ]
Farkas, K. [2 ]
Schafer, E. [3 ]
Szepes, Z. [2 ]
Szalay, B. [4 ]
Vincze, A. [5 ]
Szamosi, T. [3 ]
Molnar, T. [2 ]
Lakatos, P. [6 ]
机构：
[1] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[2] Univ Szeged, Dept Med 1, Szeged, Hungary
[3] Mil Hosp, State Hlth Ctr, Dept Gastroenterol, Budapest, Hungary
[4] Semmelweis Univ, Dept Lab Med, Budapest, Hungary
[5] Univ Pecs, Dept Med 1, Pecs, Hungary
[6] McGill Univ, Div Gastroenterol, Hlth Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.533
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P409
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [41] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Martinez-Feito, Ana
    Bravo-Gallego, Luz Yadira
    Hernandez-Breijo, Borja
    Diez, Jesus
    Garcia-Ramirez, Laura
    Jaquotot, Marta
    Plasencia-Rodriguez, Chamaida
    Nozal, Pilar
    Mezcua, Araceli
    Martin- Arranz, Maria Dolores
    Pascual-Salcedo, Dora
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [42] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Ana Martínez-Feito
    Luz Yadira Bravo-Gallego
    Borja Hernández-Breijo
    Jesús Diez
    Laura García-Ramirez
    Marta Jaquotot
    Chamaida Plasencia-Rodríguez
    Pilar Nozal
    Araceli Mezcua
    María Dolores Martín- Arranz
    Dora Pascual-Salcedo
    Scientific Reports, 10
  • [43] Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease
    Kiow, Jeremy Liu Chen
    Hoang, Thomas
    Bedi, Harjot K.
    Ardekani, Zhina Majdzadeh
    Rosenfeld, Daniel
    Reise-Filteau, Marica
    Bressler, Brian
    Leung, Yvette
    Rosenfeld, Greg
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (46)
  • [44] Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis - Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
    Glintborg, Bente
    Kringelbach, Tina Marie
    Hogdall, Estrid
    Sorensen, Inge Juul
    Jensen, Dorte Vendelbo
    Loft, Anne Gitte
    Hendricks, Oliver
    Hansen, Inger Marie Jensen
    Linauskas, Asta
    Kristensen, Salome
    Lindegaard, Hanne
    Nordin, Henrik
    Bolstad, Nils
    Warren, David
    Gehin, Johanna
    Goll, Guro Lovik
    Gron, Kathrine Lederballe
    Eng, Grith
    Enevold, Christian
    Nielsen, Claus Henrik
    Johansen, Julia Sidenius
    Hetland, Merete Lund
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry
    Glintborg, B.
    Kringelbach, T.
    Hogdall, E.
    Sorensen, I. J.
    Jensen, D. V.
    Loft, A. G.
    Hendricks, O.
    Hansen, I. M. J.
    Bolstad, N.
    Warren, D. J.
    Gehin, J.
    Goll, G.
    Gron, K. L.
    Eng, G.
    Enevold, C.
    Nielsen, C. H.
    Johansen, J. S.
    Hetland, M. L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 6 - 7
  • [46] The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
    Khan, Nabeel
    Patel, Dhruvan
    Pernes, Tyler
    Patel, Manthankumar
    Trivedi, Chinmay
    Medvedeva, Elina
    Xie, Dawei
    Yang, Yu-Xiao
    CROHNS & COLITIS 360, 2021, 3 (02)
  • [47] NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB AMONG PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE - IMPACT ON S-INFLIXIMAB AND ANTIDRUG-ANTIBODIES. RESULTS FROM THE NATIONAL DANISH RHEUMATOLOGIC BIOBANK AND THE DANBIO REGISTRY
    Glintborg, B.
    Kringelbach, T.
    Hogdall, E.
    Sorensen, I. J.
    Jensen, D. V.
    Loft, A. G.
    Hendricks, O.
    Hansen, I. M. Jensen
    Bolstad, N.
    Gron, K.
    Eng, G.
    Enevold, C.
    Nielsen, C. H.
    Warren, D.
    Goll, G.
    Gehin, J.
    Johansen, J. S.
    Hetland, M. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 224 - 224
  • [48] Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease
    Orfanoudaki, Eleni
    Foteinogiannopoulou, Kalliopi
    Theodoraki, Eirini
    Koutroubakis, Ioannis E.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (06) : E50 - E50
  • [49] Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
    Munoz-Villafranca, C.
    Arreba, P.
    Gomez, M.
    Ispizua Madariaga, N.
    Buendia, L.
    Lopez, M. L.
    Ugarte, A.
    de la Fuente, I.
    Prado, N.
    Irusta, L.
    Jimenez, M. A.
    Santa Cruz, M.
    Gonzalez, M.
    Bilbao, A.
    Ortiz de Zarate, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 723 - 723
  • [50] IMPACT OF THERAPEUTIC DRUG MONITORING ON OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hussenbux, Arif
    Chopra, Tanya
    Stearns, Rebecca
    Ravindran, Rahul
    Patodi, Nishant
    De Silva, Aminda
    GUT, 2021, 70 : A100 - A100
12345